Survival Nomogram for Patients With Thymic Carcinoma

NCT ID: NCT07179341

Last Updated: 2025-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

156 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-09

Study Completion Date

2025-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.

Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thymic Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Training cohort

156 patients diagnosed with TC accepting surgery

Group Type ACTIVE_COMPARATOR

Thymectomy for thymic carcinoma

Intervention Type PROCEDURE

Thymectomy for thymic cancer

Validation cohort one

80 patients range from June 1, 1996, to January 1, 2015 accepting surgery

Group Type PLACEBO_COMPARATOR

Thymectomy for thymic carcinoma

Intervention Type PROCEDURE

Thymectomy for thymic cancer

Validation cohort two

76 patients range from January 2, 2015, to July 1, 2023 accepting surgery

Group Type PLACEBO_COMPARATOR

Thymectomy for thymic carcinoma

Intervention Type PROCEDURE

Thymectomy for thymic cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thymectomy for thymic carcinoma

Thymectomy for thymic cancer

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
* Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
* Patients who accepted surgery should be followed up at least six months or reached the endpoint event.

Exclusion Criteria

* The patient had two types of primary tumors concurrently including TC.
* The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
* The patient did not obtain a complete pathological report after surgery.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Weijie Ye

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Weijie Ye

Resident Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SL-B2024-411-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RATT Vs. VATT for Early-stage TETs
NCT06654830 NOT_YET_RECRUITING PHASE2